Our Patients and Families

Frequently Asked Questions

What is Dravet syndrome?

Dravet syndrome is a rare, severe, treatment-resistant epilepsy syndrome with onset in infancy and serious neurodevelopmental, motor, cognitive, and behavioral consequences that persist into adulthood. Studies have reported an incidence rate for Dravet syndrome of approximately one per 16,000 live births with onset occurring within the first year of life.

For more information about the Dravet syndrome Foundation, please go to www.DravetFoundation.org and http://dravet.eu.

What is Lennox-Gastaut syndrome (LGS)?

LGS is a rare, severe form of epilepsy, marked by frequent and prolonged seizures, with peak onset between ages 3 and 5. LGS impacts approximately 14,500 to 18,500 children in the U.S. With currently available treatments, patients continue to struggle to achieve seizure control.

For more information about the LGS Foundation, please go to www.lgsfoundation.org.

What clinical trials are being conducted by Zogenix for rare epilepsies?

Zogenix is currently enrolling patients for clinical studies in LGS. For more information, go to the Fenfluramine Assessment in Rare Epilepsy – https://www.faireprogram.com/en-us for more details.

Does Zogenix have an expanded access program?

We offer a limited expanded access program (also known as “compassionate use” or “early access”) for our investigational therapy ZX008.

This website uses cookies to ensure you get the best experience on our website. Here's our cookie policy.

I Accept